Drug Trial Radar · NCT00295542
Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy
Last checked: Nov 19, 2026Latest source record: Apr 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,344
Actual
Start
Mar 2000
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- University of VigoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hospital Clinico Universitario de Santiago; Ministry of Work and Welfare - Xunta de Galicia; Ministerio de Educacion y Ciencia, Spain
- First posted
- Feb 23, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The MAPEC study was designed to investigate whether normalizing the circadian blood pressure profile towards a more dipper pattern (increasing the diurnal/nocturnal ratio of blood pressure) by the use of Chronotherapy (that is, taking into account the time of day of administration of antihypertensive medications) reduces cardiovascular risk.
Conditions
- Hypertension
Interventions
Ambulatory blood pressure monitoringDevice
Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Chronotherapy, timing of antihypertensive medicationProcedure
Comparison of effects of awakening versus bedtime dosing
ACEI (including spirapril, enalapril, quinapril, lisinopril)Drug
Treatment at awakening versus bedtime
ARB (including valsartan, telmisartan, olmesartan)Drug
Treatment at awakening versus bedtime
beta blockers (including nebivolol, atenolol, carvedilol)Drug
Treatment at awakening versus bedtime
diuretics (torasemide, indapamide, HTCZ) and doxazosinDrug
Treatment at awakening versus bedtime
Combination therapy in essential hypertensionProcedure
Treatment at awakening versus bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prognostic value of ABPM, impact of changes in ambulatory BP and impact of circadian time of antihypertensive treatment in cardiovascular, cerebrovascular and renal risk assessment.Time frame: Five years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Clinico Universitario
Santiago de Compostela, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.